Autoimmune Diseases  >>  decernotinib (VX-509)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
decernotinib (VX-509) / Vertex
NCT01052194 / 2009-017438-32: A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis

Checkmark EULAR 2014: Rheumatoid Arthritis
May 2014 - May 2014: EULAR 2014: Rheumatoid Arthritis
Checkmark Rheumatoid arthritis - ACR/ ARHP 2013
Sep 2013 - Sep 2013: Rheumatoid arthritis - ACR/ ARHP 2013
Checkmark EULAR 2013: Rheumatoid arthritis
More
Completed
2
206
US, Europe, RoW
Placebo, VX-509
Vertex Pharmaceuticals Incorporated
Rheumatoid Arthritis
07/11
07/11
NCT01754935 / 2012-003439-41: A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Completed
2
43
US, Europe, RoW
VX-509, VX-509 matching placebo
Vertex Pharmaceuticals Incorporated
Rheumatoid Arthritis
01/14
02/14
NCT01590459 / 2011-004419-22: 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Checkmark EULAR 2014: Rheumatoid Arthritis
May 2014 - May 2014: EULAR 2014: Rheumatoid Arthritis
Checkmark Moderate to severe rheumatoid arthritis
Oct 2013 - Oct 2013: Moderate to severe rheumatoid arthritis
Checkmark ACR/ARHP 2013
More
Completed
2
359
US, Europe, RoW
VX-509, VX-509 matching placebo
Vertex Pharmaceuticals Incorporated
Rheumatoid Arthritis
07/14
07/14

Download Options